Related Experiment Video
Updated: Jun 29, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
CD133 ligand-enhanced etoposide-liposome complex for targeted killing of lung cancer cells
Shiwei Nie1, Junzheng Zhou1, Xiaodong Zheng1
1Department of Thoracic Surgery, Anyang Tumor Hospital, The Affiliated Anyang Tumor Hospital of Henan University of Science and Technology, Anyang City, Henan Province, China.
Abstract:
Lung cancer has a high incidence rate and a low cure rate, hence the urgent need for effective treatment methods. Current lung cancer drugs have several drawbacks, including low specificity, poor targeting, drug resistance, and irreversible damage to normal tissues. Therefore, there is a need to develop a safe and effective new drug that can target and kill tumor cells. In this study, we combined nanotechnology and biotechnology to develop a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for targeted therapy of lung cancer. The CD133 ligand targeted lung cancer stem cells, causing the composite material to aggregate at the tumor site, where high levels of ETP liposomes could exert a strong tumor-killing effect. Our research results demonstrated that this nano-drug had efficient targeting and tumor-killing effects, indicating its potential for clinical application.
Insights
This study developed a novel nano-drug, Lipo@ETP-CD133, for targeted lung cancer therapy. The drug effectively targets cancer stem cells, enhancing tumor cell killing with reduced side effects.
Area of Science:
- Oncology
- Nanotechnology
- Biotechnology
Background:
- Lung cancer presents a high incidence and low cure rate, necessitating advanced treatments.
- Existing therapies face challenges like poor specificity, drug resistance, and damage to healthy tissues.
- There is a critical need for novel, targeted drugs to effectively eliminate tumor cells.
Purpose of the Study:
- To develop a targeted drug delivery system for lung cancer using nanotechnology and biotechnology.
- To create a CD133 ligand-modified etoposide-liposome complex (Lipo@ETP-CD133) for enhanced lung cancer therapy.
Main Methods:
- Combination of nanotechnology and biotechnology to synthesize Lipo@ETP-CD133.
- Utilizing a CD133 ligand for specific targeting of lung cancer stem cells.
- Evaluating the drug's aggregation at the tumor site and its cytotoxic effect.
Main Results:
- The nano-drug, Lipo@ETP-CD133, demonstrated efficient targeting capabilities.
- Significant tumor-killing effects were observed due to localized high concentrations of etoposide liposomes.
- The targeted approach showed potential for minimizing damage to normal tissues.
Conclusions:
- Lipo@ETP-CD133 exhibits promising targeted therapy potential for lung cancer.
- This nanotechnology-based approach offers a safer and more effective treatment strategy.
- Further clinical applications are indicated by the study's positive outcomes.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:54MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
